Last reviewed · How we verify
CD30.CAR-EBVST cells
CD30.CAR-EBVST cells is a CAR T-cell therapy Biologic drug developed by Baylor College of Medicine. It is currently in Phase 1 development. Also known as: Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes.
Genetically modified T cells that target CD30-expressing cancer cells while retaining activity against EBV-infected cells.
CD30.CAR-EBVST cells are a type of immunotherapy used to treat CD30-positive lymphomas, including diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and peripheral T-cell lymphoma. They are a form of chimeric antigen receptor (CAR) T cells that are modified to recognize and target CD30-positive cancer cells.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CD30.CAR-EBVST cells |
|---|---|
| Also known as | Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes |
| Sponsor | Baylor College of Medicine |
| Drug class | CAR T-cell therapy |
| Modality | Biologic |
| Phase | Phase 1 |
Mechanism of action
These cells are Epstein-Barr virus-specific T cells engineered with a chimeric antigen receptor (CAR) directed against CD30, a surface protein expressed on certain lymphomas. The dual functionality allows targeting of CD30-positive tumors while maintaining anti-viral immunity against EBV.
Approved indications
Common side effects
Key clinical trials
- Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas (PHASE1)
- Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas (PHASE1)
- Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD30.CAR-EBVST cells CI brief — competitive landscape report
- CD30.CAR-EBVST cells updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI
Frequently asked questions about CD30.CAR-EBVST cells
What is CD30.CAR-EBVST cells?
How does CD30.CAR-EBVST cells work?
Who makes CD30.CAR-EBVST cells?
Is CD30.CAR-EBVST cells also known as anything else?
What drug class is CD30.CAR-EBVST cells in?
What development phase is CD30.CAR-EBVST cells in?
Related
- Drug class: All CAR T-cell therapy drugs
- Manufacturer: Baylor College of Medicine — full pipeline
- Also known as: Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing